Furthermore, treatment of 22Rv1, LNCaP95, and VCaP PCa cells with an MCL1 specific inhibitor (1 μM AZD5991) led to increased caspase 3/7 activation and reduced cell viability (Figure 2C).33 Here, MCL1 is linked to posterior cortical atrophy.